Philadelphia, Pennsylvania, United States · Est. 2002
Amicus Therapeutics is a biopharmaceutical company focused on developing therapies for rare genetic diseases, particularly lysosomal storage disorders.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 1
R&D Momentum
35/100
Pipeline Velocity
11/100
Trial Completion Rate
85/100
Pipeline Concentration
56/100
Pipeline Freshness
73/100
Strategic Signals
Activity
Last 14 days
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease
A Prospective, Observational Study of Patients With Fabry Disease (US Specific)
Earlier
Details
Company Overview
—
Mkt Cap
$399.4M
Revenue
$247.0M
Cash
Therapeutic Focus
Recent SEC Filings
AMICUS THERAPEUTICS, INC. (FOLD) (CIK 0001178879)
Pipeline
Regulatory
Galafold — GALAFOLD
Application NDA208623 (NDA)
Cipaglucosidase alfa — POMBILITI
Application BLA761204
Cipaglucosidase alfa — POMBILITI
Application BLA761204
AMICUS THERAPEUTICS, INC. (FOLD) (CIK 0001178879)
Accession: 001-33497
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)